A recent study demonstrated a beneficial safety profile and satisfactory efficacy for AAV2-mediated delivery of the BEST1 gene to reverse key ultrastructural and molecular Best disease characteristics in a naturally occurring canine Best disease model [119]. This evidence concerns the gene BEST1 and Best vitelliform macular dystrophy.